Biosimilars for Arthritis: What New U.S. Policy and Market Changes Mean for Patients in 2026

Why this matters in 2026

If you live with rheumatoid arthritis, psoriatic arthritis, or another inflammatory joint disease, biologic drugs can be life-changing—but also extremely expensive.

Over the past two years, two major shifts have reshaped that landscape:

A rapid expansion of FDA-approved biosimilars for adalimumab (the drug originally sold as Humira), one of the most widely used arthritis biologics.
A redesign of Medicare Part D that now includes a $2,000 annual out-of-pocket cap on prescription drugs, which took effect in 2025.

Together, these changes are increasing competition and limiting annual drug spending for many Medicare beneficiaries. But savings and access still depend heavily on your specific insurance plan.

Here’s what patients and families should understand.

What Is a Biosimilar?

Biologic drugs are made from living cells and are more complex than traditional pills. Because of that complexity, they cannot be copied exactly the way generic drugs are.

According to the U.S. Food and Drug Administration (FDA), a biosimilar is a product that is “highly similar” to an already-approved biologic (called the reference product) and has no clinically meaningful differences in safety, purity, or effectiveness.

That does not mean biosimilars are identical copies. Instead, the FDA requires extensive analytical testing, animal data, and clinical studies to show that any differences do not affect how the drug works in patients.

What does “interchangeable” mean?

Some biosimilars receive an additional FDA designation called interchangeable. This means the product meets extra requirements showing that patients can switch back and forth between the biosimilar and the reference product without reduced effectiveness or increased risk.

Whether a pharmacist can automatically substitute an interchangeable biosimilar depends on state law and health plan rules. Not all biosimilars are interchangeable, and not all substitutions happen at the pharmacy counter—many are driven by insurance formularies instead.

The Adalimumab Wave: Why It’s a Big Deal for Arthritis

Adalimumab, originally sold as Humira, treats:

Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Juvenile idiopathic arthritis
Inflammatory bowel diseases
Plaque psoriasis

For years, Humira was the top-selling prescription drug in the United States. In 2023 and 2024, multiple adalimumab biosimilars entered the U.S. market following FDA approval. The FDA’s approved biosimilar product list now includes numerous adalimumab alternatives.

This matters because increased competition typically lowers list prices. Several adalimumab biosimilars launched with list prices significantly below the original brand price.

However, list price is not the same as what patients pay. Insurance design, rebates negotiated by pharmacy benefit managers, and formulary placement still shape real-world costs.

Medicare Part D Redesign: The $2,000 Out-of-Pocket Cap

The second major change affecting arthritis patients is federal policy.

Under the Inflation Reduction Act, Medicare Part D was redesigned starting in 2025. According to the Centers for Medicare & Medicaid Services (CMS), beneficiaries now have a $2,000 annual cap on out-of-pocket prescription drug spending.

For people using high-cost biologics, this is significant.

What changed?

The coverage “donut hole” was eliminated.
Once a beneficiary hits $2,000 in out-of-pocket costs for covered Part D drugs in a calendar year, they pay $0 for covered medications for the rest of that year.
A monthly payment smoothing option allows beneficiaries to spread costs over the year.

Before 2025, patients using biologics could face thousands of dollars in ongoing cost-sharing. Now, annual exposure is capped for Part D enrollees.

Independent policy analysis from KFF explains that this redesign particularly benefits people with very high drug costs, including those using specialty biologics.

Important limitation

The cap applies to Part D drugs. Some infused biologics may be covered under Medicare Part B instead, with different cost-sharing rules.

Why Savings Still Vary by Patient

Even with more biosimilars and a Part D cap, not every patient will see the same financial impact.

1. Formularies and tiers

Health plans decide which drugs are preferred. A plan may favor a specific biosimilar—or sometimes even the original brand—based on negotiated rebates.

2. Prior authorization and step therapy

Some plans require patients to try one drug before approving another. Switching may be driven by insurer policy rather than clinical need.

3. Commercial insurance differences

The $2,000 cap applies to Medicare Part D, not to employer or marketplace plans. Commercial insurance cost-sharing varies widely.

4. Pharmacy substitution rules

Even when a biosimilar is designated interchangeable, state substitution laws and plan contracts influence whether automatic substitution happens.

Lower list prices increase competition, but they do not automatically translate into lower out-of-pocket costs for every individual.

Switching Safely: What Patients Should Ask

The American College of Rheumatology states that biosimilars are expected to perform similarly to their reference biologics. Still, switching should be a shared decision.

If your insurer or pharmacy proposes a switch, consider asking:

Is this product FDA-approved for my exact condition?
Is it interchangeable, or is this a formulary-driven change?
How will we monitor my disease activity after switching?
What should I watch for in terms of flare symptoms?
What happens if my arthritis control worsens?

Most patients transition without problems, but monitoring is standard practice. Keep track of joint pain, morning stiffness, swelling, fatigue, and function. Report changes promptly.

What This Means for Arthritis Patients in 2026

Here are the practical takeaways:

Biosimilars are FDA-reviewed drugs shown to be highly similar in safety and effectiveness to existing biologics.
Multiple adalimumab biosimilars are now available in the United States, increasing market competition.
Medicare Part D now includes a $2,000 annual out-of-pocket cap, which may substantially limit yearly spending for beneficiaries using high-cost biologics.
Your actual savings depend on your specific insurance plan, formulary tier, and authorization rules.
Before switching medications, discuss monitoring and follow-up with your rheumatologist.

For many people with inflammatory arthritis, these changes improve predictability and may reduce financial strain. But they do not eliminate complexity.

The best next step is to review your current plan’s formulary, confirm how your medication is covered in 2026, and talk with your rheumatology team before making changes.

Access to biologics is evolving. Staying informed—and asking questions—remains one of the most important tools patients have.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.